IL-6/JAK/STAT3信号通路在前列腺癌发展和治疗中的研究进展

doi:10.16352/j.issn.1001-6325.2022.01.025

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 159-162.doi: 10.16352/j.issn.1001-6325.2022.01.025

IL-6/JAK/STAT3信号通路在前列腺癌发展和治疗中的研究进展

陈号¹, 陈韬², 吴静^1*

1.昆明医科大学生物化学与分子生物学系,云南昆明 650500;
2.昆明医科大学第二附属医院泌尿外科,云南昆明 650101

收稿日期:2021-04-15 修回日期:2021-08-13 出版日期:2022-01-05 发布日期:2022-01-05
通讯作者: ^* wujingkm176@126.com
基金资助:
云南省科技厅-昆明医科大学应用基础研究联合专项资金[2018FE001(-237)]

Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer

CHEN Hao¹, CHEN Tao², WU Jing^1*

1. Department of Biochemistry and Molecular Biology, Kunming Medical University, Kunming 650500;
2. Department of Urology, the Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

Received:2021-04-15 Revised:2021-08-13 Online:2022-01-05 Published:2022-01-05
Contact: ^* wujingkm176@126.com

摘要/Abstract

摘要： IL-6/JAK/STAT3是IL-6激活的显著的信号通路之一。IL-6、p-STAT3在前列腺癌(PCa)组织和转移瘤中高表达,在诱导PCa发生、促进肿瘤细胞增殖、侵袭和转移中起着关键作用,并且通过激活雄激素受体(AR)参与PCa去势抵抗和肿瘤耐药。 IL-6/JAK/STAT3及其激活的下游因子在肿瘤进展中的多种角色为化疗药物开发提供了良好的基础,目前,许多靶向抑制剂已被证明可有效抑制肿瘤进展,有望研发出更多有效药物。

关键词: 前列腺癌, 去势抵抗性前列腺癌, 白细胞介素-6, 信号传导与转录激活因子3(STAT3)

Abstract: IL-6/JAK/STAT3 is one of the most significant signaling pathways activated by IL-6.IL-6 and p-STAT3 which are highly expressed in prostate cancer (PCa) tissue and metastatic tumors So this pathway may play a role in the occurrence of prostate cancer, promotion of malignant cell proliferation, invasion and metastasis of the tumor. It may also function in the development of castration resistance and drug resistance through activation androgen receptor(AR). The multiple roles of IL-6/JAK/STAT3 and its activated downstream factors in tumor progression provide a good basis for the development of chemotherapy drugs. Currently, many targeted inhibitors have been proved to be effective in inhibiting tumor progression and more effective drugs are expected to be developed.

Key words: prostate cancer, castration-resistant prostate cancer, interleukin-6, signal transducer and activator of transcription (STAT3)

中图分类号:

R737.25

陈号, 陈韬, 吴静. IL-6/JAK/STAT3信号通路在前列腺癌发展和治疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 159-162.

CHEN Hao, CHEN Tao, WU Jing. Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer[J]. Basic & Clinical Medicine, 2022, 42(1): 159-162.

参考文献

[1]Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33.
[2]付振涛, 郭晓雷, 张思维, 等. 2015年中国前列腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2020: 718-722.
[3]Rojas A, Liu G, Coleman I, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR[J]. Oncogene, 2011, 30: 2345-2355.
[4]Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation[J]. Biochem J, 2014, 462: 1-13.
[5]张锦锦, 唐慧. JAK/STAT3信号通路调控肿瘤及其相关生物功能的研究进展[J]. 基础医学与临床, 2017, 37: 1456-1460.
[6]Liu G, Zhang J, Frey L, et al. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue[J]. J Hematol Oncol, 2017, 10: 14. doi: 10.1186/s13045-13016-10386-13047.
[7]Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue[J]. J Pathol, 2000, 191: 239-244.
[8]Handle F, Puhr M, Schaefer G, et al. The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models[J]. Mol Cancer Ther, 2018, 17: 2722-2731.
[9]Don-Doncow N, Marginean F, Coleman I, et al. Expres-sion of STAT3 in prostate cancer metastases[J]. Eur Urol, 2017, 71: 313-316.
[10]Lee SO, Lou W, Johnson CS, et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway[J]. Prostate, 2004, 60: 178-186.
[11]Schroeder A, Herrmann A, Cherryholmes G, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling[J]. Cancer Res, 2014, 74: 1227-1237.
[12]Xu L, Chen X, Shen M, et al. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels[J]. Mol Oncol, 2018, 12: 269-286.
[13]Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experi mental prostate cancer metastases formation[J]. Mol Cancer Ther, 2014, 13: 1246-1258.
[14]Armakolas A, Dimakakos A, Loukogiannaki C, et al. IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors[J]. Mol Med, 2018, 24: 6.doi: 10.1186/s10020-10018-10003-z.
[15]Wang X, Lee SO, Xia S, et al. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals[J]. Mol Cancer Ther, 2013, 12: 1026-1037.
[16]Thaper D, Vahid S, Kaur R, et al. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer[J]. Sci Rep, 2018, 8: 17307.doi: 17310.11038/s41598-17018-35612-z.
[17]Hu F, Zhao Y, Yu Y, et al. Docetaxel-mediated auto-phagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3[J]. Cancer Lett, 2018, 416: 24-30.
[18]Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2[J]. J Cancer Res Clin Oncol, 2019, 145: 1471-1484.
[19]Huang S, Liu Q, Liao Q, et al. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression[J]. Cancer Sci, 2018, 109: 678-687.
[20]Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer[J]. Nat Rev Clin Oncol, 2018, 15: 234-248.
[21]Han Z, Wang X, Ma L, et al. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in pr ostate cancer[J]. Oncotarget, 2014, 5: 8416-8428.
[22]Canesin G, Evans-Axelsson S, Hellsten R, et al. The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer[J]. Eur Urol, 2016, 69: 400-404.
[23]Hellsten R, Lilljebjörn L, Johansson M, et al. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors[J]. Prostate, 2019, 79: 1611-1621.
[24]Lee JH, Kim C, Baek SH, et al. Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer[J]. Oncotarget, 2017, 8: 17700-17711.
[25]Wang X, Wang B, Zhou L, et al. Ganoderma lucidum put forth anti-tumor activity against PC-3 prostate cancer cells via inhibition of Jak-1/STAT-3 activity[J]. Saudi J Biol Sci, 2020, 27: 2632-2637.
[26]Ghandadi M, Sahebkar A. Curcumin: an effective inhibi-tor of interleukin-6[J]. Curr Pharm Des, 2017, 23: 921-931.

IL-6/JAK/STAT3信号通路在前列腺癌发展和治疗中的研究进展

Research progress on IL-6/JAK/STAT3 in the development and treatment of prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[2]	刘彼得, 李循, 王书恒, 靳宏勇, 张小安, 李九智. miR-146a-5p靶向SMAD4抑制人前列腺癌细胞系PC-3增殖和侵袭[J]. 基础医学与临床, 2023, 43(8): 1215-1221.
[3]	周智恩, 严维刚, 周毅, 左宇志, 梁震. 拼图(Jigasaw)教学法应用于前列腺靶向穿刺教学中的效果评估[J]. 基础医学与临床, 2022, 42(5): 844-847.
[4]	刘冬梅, 徐强, 李峰. 土荆皮乙酸诱导人前列腺癌细胞系DU145凋亡[J]. 基础医学与临床, 2022, 42(10): 1555-1560.
[5]	冯天瑞, 严维刚. 环状RNAs在前列腺癌中的研究进展[J]. 基础医学与临床, 2022, 42(1): 179-183.
[6]	李英杰, 杨庭楷, 纪志刚, 文进. 外泌体在前列腺癌诊疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 163-167.
[7]	程继, 付国, 赵华才, 王志刚, 高丹, 董青川. 姜黄素提高人前列腺癌细胞系PC-3放疗敏感性[J]. 基础医学与临床, 2021, 41(12): 1792-1796.
[8]	周智恩李汉忠严维刚. 雄激素受体蛋白表达及其基因获得/缺失与前列腺癌预后的相关性[J]. 基础医学与临床, 2010, 30(8): 857-861.
[9]	严维刚;李汉忠;周毅;崔全才. 前列腺癌空间分布特点的临床分析[J]. 基础医学与临床, 2010, 30(12): 1325-1328.
[10]	何旺祝志臻程志强王扬李鸣. PIAS3敲低对前列腺癌细胞增殖和凋亡的影响[J]. 基础医学与临床, 2008, 28(5): 469-472.